Post-transplant diabetes mellitus

Journal of Nephrology

Volumn 16, Issue 5, 2003, Pages 626-634

  Salvadori, Maurizio ^a   Bertoni, Elisabetta ^a   Rosati, Alberto ^a   Zanazzi, Maria ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Cardiovascular complications; Diabetes mellitus; Immunosuppresive regimens; Patients and graft survival; Post transplant complications; Risk factors

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; DRUG METABOLITE; FIBRIC ACID DERIVATIVE; GLUCOCORTICOID; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INSULIN; LIPID; LONG ACTING DRUG; METFORMIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL ANTIDIABETIC AGENT; PREDNISOLONE; RAPAMYCIN; STEROID; SULFONYLUREA DERIVATIVE; TACROLIMUS; CALCINEURIN;

AGING; ATTENTION; BODY MASS; BODY WEIGHT; BONE DISEASE; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIET THERAPY; DISEASE CONTROL; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG USE; DYSLIPIDEMIA; ETHNOLOGY; FREQUENCY ANALYSIS; GLUCOSE INTOLERANCE; GRAFT INFECTION; GRAFT SURVIVAL; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INSULIN RESISTANCE; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LACTIC ACIDOSIS; LIPID BLOOD LEVEL; METABOLIC REGULATION; MORTALITY; OBESITY; OSTEOPENIA; PATHOGENESIS; PATIENT SELECTION; POSTOPERATIVE COMPLICATION; PREOPERATIVE EVALUATION; PREVENTION; QUALITY OF LIFE; RECIPIENT; REVIEW; RISK FACTOR; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT PLANNING; VASCULAR DISEASE; DRUG ANTAGONISM;

CALCINEURIN; DIABETES MELLITUS; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; RISK FACTORS; SURVIVAL RATE;

EID: 1442282931     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Arner P, Gunnarsson R, Blomdahl S, Groth CG. Some characteristics of steroid diabetes: a study in renal-transplant recipients receiving high-dose corticosteroids therapy. Diabetes Care 1983; 6: 23-5.
2. Hjelmesaeth J, Hartmann A, Kosstad J, Stenstrom J, Leivestad T, Egeland T, Fauchald P. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997; 64: 979-83.
3. Hjelmesaeth J, Hartmann A, Kosstad J, Egeland T, Stenstrom J, Fauchald P. Tapering off prednisolone and cyclosporine the first year after renal transplantation: the effect on glucose tolerance. Nephrol Dial Transplant 2001; 16: 829-35.
4. Jindal RM. Post-transplant diabetes mellitus: a review. Transplantation 1994; 58: 1289-98.
5. Roth D, Milgrom M, Esquenazi V, Fuller L, Burke G, Miller J. Post-transplant hyperglycaemia: increased incidence in cyclosporine-treated renal allograft recipients. Transplantation 1989; 47: 278-81.
6. Tanabe K, Koga S, Takahashi K, Sonda K, Tokumoto T, Babazono T, Yaisawa T, Toma H, Kawai T, Fuchinoue S, Teraoka S, Ota K. Diabetes mellitus after renal transplantation under FK506 (tacrolimus) as primary immunosuppression. Transplant Proc 1996; 28: 1304-5.
7. Weir MR, Fink JC. Risk for post-transplant diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis 1999; 34: 1-13.
8. Krentz AJ, Dousset B, Meier D, McMaster P, Buckels J, Cramb R, Smith JM, Nattrass M. Metabolic effects of cyclosporine A and FK506 in liver transplant recipients. Diabetes 1993; 42: 1753-9.
9. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997; 63: 977-83.
10. Shapiro R, Cantlebury WP, Jordan ML. Paediatric renal transplantation under tacrolimus-based immunosuppression. Transplantation 1999; 67: 299-303.
11. Johnson C, Ahsan N, Gomwa T, Halloran P, Stegal M, Harby M, Metzger R. Randomised trial of tacrolimus (prograf) in combination with azathioprine or micophenolate mofetil vs cyclosporine (neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000; 69: 834-41.
12. Miller J, Mendez R, Pirsch JD, Jensik FC. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients: FK 506/MMF dose ranging kidney transplant study group. Transplantation 2000; 69: 875-80.
13. Woodward RS, Schnitzler RA, Baty J, Lowell J, Lopez-Rocafort L, Heider S, Woodworth TJ, Brennan DC. Incidence and cost of diabetes mellitus among US wait-listed and transplanted renal allograft recipients. Am J Transplant 2003; 3: 590-8.
14. Reisaeter AV, Hartmann A. Risk factors and incidence of posttransplant diabetes mellitus. Transplant Proc 2001; 33 (suppl 5A): S8-18.
15. American Diabetes Association. Diabetes Care 2001; 24: 34S.
16. Kasiske BL, Sneyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2002; 2 (suppl 3): S225.
17. Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC. Post-transplantation diabetes. Diabetes Care 2002; 25: 583-92.
18. Noble S, Markham A. Cyclosporine: a review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion based formulation. Drugs 1995; 50: 924-41.
19. Spencer CM, Goa KL, Gillis JC. Tacrolimus: an update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997; 54: 925-75.
20. Jindal RM, Sidner RA, Milgrom ML. Post-transplant diabetes mellitus. The role of immunosuppression. Drug Saf 1997; 16: 242-57.
21. Jain A, Khanna A, Molmenti EP, Rishi N, Fung JJ. Immunosuppressive therapy. Surg Clin North Am 1999; 79: 59-76.
22. Cavaille-Coll MW, Elashoff MR. Commentary on a comparison of tacrolimus and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1998; 65: 142-3.
23. Marchetti P, Navalesi R. The metabolic effects of cyclosporine and tacrolimus. J Endocrinol Invest 2000; 23: 482-90.
24. Saudek F, Pelikanova T, Bartos V, Reneltova I, Kazdova L, Kovar J, Karasova L. Insulin action and insulin binding following pancreas transplantation. Diabetologia 1991; 34 (suppl 1): S71-5.
25. Berwerck S, Kahl A, Bechstein W, Platz K, Muller U, Neuhaus P, Frei U. Clinical rise of the euglicemic hyperinsulinemic clamp for diagnosis of tacrolimus-induced insulin resistance after combined pancreas-kidney transplantation. Transplant Proc 1998; 30: 1944-5.
26. Basadonna G, Montorsi F, Dakizaki K, Merrell RC. Cyclosporine A and islet function. Am J Surg 1988; 156: 191-3.
27. Bani Sacchi T, Bani D, Filipponi F, Mickel A, Houssin D. Immunocytochemical and ultra structural changes of islet cells in rats treated long-term with cyclosporine at immunotherapeutic doses. Transplantation 1990; 49: 982-7.
28. Martin F, Bedoya FJ. Mechanisms of action of cyclosporine A on islet alfa-and beta cells. Effects on cAMP and calcium dependent pathways. Life Sci 1991; 49: 1915-21.
29. Hirano Y, Fujihira S, Ohara K, Katsuki F, Noguchi H. Morphological and functional changes of islets of Langherans in FK506-treated rats. Transplantation 1992; 53: 889-94.
30. Redmond JB, Olson LK, Armstrong MB, Greene MJ, Robertson RP. Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest 1996; 98: 2786-93.
31. Ishizuka J, Guiuzza KK, Wassmuth Z, Hsieh J, Sato K, Tsuchiya T, Towesend CM, Fish JC, Thomson JC. Effects of FK506 and cyclosporine on dynamic insulin secretion from isolated dog pancreatic islet. Transplantation 1993; 56: 1486-90.
32. Noguchi N, Takasawa S, Nata K, Tohgo A, Kato I, Ikehata F, Yonekura H, Okamoto H. Cyclic ADP-ribose binds to FK506 binding protein 12.6 to release calcium++ from islet microsome. J Biol Chem 1997; 272: 3133-6.
33. Maes BD, Kuypers D, Messian T, Evenepoel P, Mathieu C, Coosemans W, Pirenne J, Vanrenterghem YF. Post-transplantation diabetes mellitus in FK506-treated renal transplant recipients: Analysis of incidence and risk factors. Transplantation 2001; 72: 1655-61.
34. Andrews RC, Wolker BR. Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci 1999; 96: 513-23.
35. Henriksen JE, Alford F, Ward GM, Beck-Nielsen H. Risk and mechanism for dexamethazone-induced deterioration of glucose tolerance in non-diabetic first degree relatives of NIDDM patients. Diabetologia 1997; 40: 1439-48.
36. Boots JM, Van Duijnhoven EM, Christiaans MH, Wolffenbuttel BH, Van Hooff JP. Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol 2002; 13: 221-27.
37. Vanrenterghem Y. Strategies to reduce or replace steroid dosing. Transplant Proc 1999; 31 (suppl 8A): S7-10.
38. Nylan JF for the FK506 kidney transplant study group. Racial differences in renal transplantation after immunosuppression with tacrolimus vs cyclosporine. Transplantation 1998; 65: 515-23.
39. Sumrani NB, Delaney V, Ding Z, Devils R, Daskalakis P, Friedman EA, Butt KM. Diabetes mellitus after renal transplantation in the cyclosporine era : an analysis of risk factors. Transplantation 1991; 51: 343-47.
40. Hathaway DK, Tolley EA, Blakely ML, Winsett RP, Gaber AO. Development of an index to predict post-transplant diabetes mellitus. Clin Transplant 1994; 7: 330-8.
41. Rao M, Jacob CK, Shastry JC. Post-renal transplant diabetes mellitus: a retrospective study. Nephrol Dial Transplant 1992; 7: 1039-42.
42. Keen H, Jarret RJ, Mc Cartney P. The ten-year follow-up of the Bedford survey (1962-1972): glucose tolerance and diabetes. Diabetologia 1982; 22: 73-8.
43. Vesco L, Busson M, Bedrossian J, Bitker MO, Hiesse C, Lang P. Diabetes mellitus after renal transplantation. Transplantation 1996; 61: 1475-8.
44. Parikh C, Klem P, Wong C, Chan L. Obesity as an independent predictor of post-transplant diabetes mellitus (PTDM). Am J Transplant 2002; 2 (suppl 3): S420.
45. Jawad F, Rizvi SA. Post-transplant diabetes mellitus in live-related renal transplantation. Transplant Proc 2000; 32: 1888.
46. Sumrani N, Delaney V, Ding Z, Davis R, Daskalakis P, Friedman EA, Butt KM, Hong JH. Post-transplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplant Proc 1991; 23: 1249-50.
47. Al-Uzri A, Stablein DM, Cohn RA. Post-transplant diabetes mellitus in pediatric renal transplant recipients: a report of the north American pediatric renal transplant cooperative study (NAPRTCS). Transplantation 2001; 72: 1020-4.
48. De Mattos AM, Prather J, Al-Uzri A, Olyaei AJ, Golconda M, Barry JM, Norman DJ. Autosomal dominant polycystic kidney disease (ADPKD) as risk factor for the development of post-transplant diabetes mellitus (PTDM). Am J Transplant 2002; 2: S359.
49. Cosio FG, Pesavento TE, Kim S, Osei K, Henry M, Ferguson RM. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int 2002; 62: 1440-6.
50. Revanur VK, Jardine AG, Kingsmore DB, Jacques BC, Hamilton DH, Jindal RM. Influence of diabetes mellitus on patients and graft survival in recipients of kidney transplantation. Clin Transplant 2001; 15: 89-94.
51. Lindholm A, Albrechtsen D, Frodin L, Tufveson G, Persson NH, Lundgren G. Ischemic heart disease: major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 1995; 60: 451-7.
52. Thomas MC, Mathew PH, Russ GR, Mohan MR, Moran J. Early perioperative glycemic control and allograft rejection in patients with diabetes mellitus: a pilot study. Transplantation 2001; 72: 1321-4.
53. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kuseck JV, Stricker G. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of diet in renal disease study group. N Engl J Med 1994; 330: 877-84.
54. Noble NA, Border WA. Angiotensin II in renal fibrosis. Should TGF-beta rather than blood pressure be the therapeutic target? Semin Nephrol 1997; 17: 455-66.
55. Miles AM, Sumrani N, Horowitz R, Homel P, Maursky V, Markell MS, Distant DA, Hong JH, Sommer BG, Friedman EA. Diabetes mellitus after renal transplantation. Transplantation 1998; 65: 380-4.
56. Boudreaux JP, McHugh L, Canafax DM, Ascher N, Sutherland DE, Payne W, Simmons RL, Najarian JS, Fryd DS. The impact of cyclosporine combination immunosuppression on the incidence of post-transplant diabetes in renal allograft recipients. Transplantation 1987; 44: 376-81.
57. Friedman EA, Shyh T, Beyer M, Manis T, Butt KM. Post-transplant diabetes in kidney transplant recipients. Am J Nephrol 1985; 5: 196.
58. Lanerolle RD, de Abrew K, Fernando DJ, Sheriff MH. Post-transplant diabetes in Sri Lanka. Transplant Proc 1996; 28: 1945-7.
59. von Kiparsky A, Frei D, Uhlschmid G, Largiader F, Binswanger U. Post-transplant diabetes mellitus in renal allograft recipients: a matched pair control study. Nephrol Dial Transplant 1990; 5: 220-5.
60. Hjelmeseth J, Hartmann A, Midvedt K, Aakhus S, Stenstrom J, Morkrid L, Egeland T, Tordarson H, Fauchald P. Metabolic cardiovascular syndrome after renal Transplantation. Nephrol Dial Transplant 2001; 16: 1047-52.
61. Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996; 7: 158-75.
62. Aakhus S, Dahl K, Wideroe TE. Cardiovascular morbidity and mortality in renal transplant recipients. Results from a 5-year follow-up. Nephrol Dial Transplant 1997; 12: 231.
63. Lamarche B, Tchernof A, Mauriege P, Cantin B, Dagenaif GR, Lupien PJ, Destres JP. Fasting insulin and apolipoprotein B levels and low density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998; 279: 1955-61.
64. Markell M. Clinical impact of post-transplant diabetes mellitus. Transplant Proc 2001; 33 (suppl 5A): S19-22.
65. Chiu MY, Sprague SM, Bruce DS, Woodle ES, Thistlethwaite JR, Josethson MA. Analysis of fracture prevalence in kidney-pancreas allograft recipients. J Am Soc Nephrol 1998; 9: 677-83.
66. Marchetti P. Strategies for risk reduction and management of post-transplant diabetes mellitus. Transplant Proc 2001; 33 (suppl 5A): S27-31.